H. pylori treatment regimens should achieve 70% minimum cure rate -- FDA draft guidance.
Executive Summary
H. PYLORI REGIMENS SHOULD ACHIEVE MINIMUM CURE RATE OF 70%, FDA recommends in its draft guidance to industry on "Evaluating Clinical Studies of Antimicrobials in the Division of Anti-Infective Drug Products." The draft states that "the minimum number of patients recommended in a [Helicobacter pylori] study would be 178 if the mean cure rate is 70% and the lower 95% confidence limit is 60%." An advisory committee meeting to discuss the draft guidance has been scheduled for March 5-7 ("The Pink Sheet" Feb. 17, In Brief).
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth